EvaluatePharma - Schering-Plough - Worldwide

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	3 NOV 2009: Merck & Co acquired Schering-Plough in a reverse takeover in which Schering-Plough will remain as the surviving company, trading under the name Merck & Co. Schering-Plough (SGP), was a global provider of healthcare products. Business segments include: Animal health, Health Care Products (Foot Care/ Sun Care/ OTC).
Listed or Private Company	Listed
Company Classification	Global Majors
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
7/28/2009	28 Jul: Shares fall despite the release of an FDA memo, ahead of an FDA advisory panel meeting on 30 Jul, stating that the company's antipsychotic drug, Saphris, appears to be effective and as safe as other similar medications.	42,989	-1.8%	-784

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Remicade	infliximab	Other anti-rheumatics	1,648²	2,118³	+29%
2	Nasonex	mometasone furoate	Corticoids	1,092⁴	1,155⁵	+6%
3	Temodar/Temodal	temozolomide	Alkylating agents	861⁶	1,002⁷	+16%

Note: Shaded Cells⁸

Therapy Area Focus in 2008

Schering-Plough
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Blood	314
Cardiovascular⁹	167
Central Nervous System	476
Dermatology¹⁰	406
Gastro-Intestinal	115
Genito-Urinary	1,885
Musculoskeletal	2,371
Oncology & Immunomodulators	2,527
Respiratory¹¹	3,257
Systemic Anti-Infectives	933
Other Rx & OTC Pharma	4,257¹²

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Schering-Plough ¹³	269

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Merck continues to play down J&J arbitration but risk remains (August 03, 2010)

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXXX XX $X:
X) +XXXX

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX X:
XXXXXXXX XX XXXXXXXX XXXX XXX XXXXXXXXXXXX XX XXXXXXXX, XXX., X XXXXXXX & XXXXXXX XXXXXXX. XXXXXX XXXX, XXXXXXXX-XXXXXX XXXXXXXXX XX XXXXXX XXXXX XXX XXXXXXXX XXXX XXXXXXXX XXX XXXXXXX XXXXXX XX XXXXXXX XXX XXXXXXXXXXXXX XXXXXXXXX, X XXXXX XXXXX XXXXXXXXXX XXXXXXXX XXXXXXXXX XX XXXXX XXX XXXXXX. XXXXXXXX-XXXXXX XXX XXXXXXXXX XXXXXXXXX XXXXXX XX XXXX XXXXXXXX XXXXXXX XX XXX X.X., XXXXX XXX XXXXXXX XXXXX XXXXXXX. XX XXXXXXXX XXXX, XXXXXXXX-XXXXXX XXX XXXXXXXX XXXXXXX XXXXX XXXXXXXXXXXX XXXXXXXXX XXXXXXXXX XXX XXXXXXXXXXX, XXXXXXXXXXXXXXXXX XXX XXXXXXXXXXXX XX XXXX XXXXXXXX XXX XXXXXXXXX, XXXXXXXXX XXXXXXXX-XXXXXX’X XXXXXX XX XXXXXXXXXXX XXXXXX XXXXXXXX XX XXXXX XXX XXXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXXXXX XXXXXXXXX XXXXXX XXX XXXXXXXXX. XXXXXXXXX XXXX XXXXXXXXXX XXXXXXXX XX XXXXXXXXX XX XXX XX, XXXXXXXX-XXXXXX’X XXXXXXXXX XXXXXX XXX XXXX XXXXXXXX XXXX XXX XXXXXX XXX XX XXXXX XXXXX XXX XXXXX XXXXXXXXXX XXXX XX XXXXXXXXX XXXXXX XXX XX. XXXXXXXX XXXX XXXXXXX X XXXXXXXXXXXXX XXXXXXXXX XXXXX XX XXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXXXXXXXX XX XXXX XXXXXXXX XX XXX XXXXXXXX-XXXXXX XXXXXXXXX XXXXXXXXX XXXXXXX XXXX XXX XXXX, XXX XXX XXXXX XX XXXXXXX XXXX XXXXXX XXXXX XXXXXXXXXX XXX XXX XXXXXXXXX XX XXX XXXX. XXX XXXXXXX XX XXX XXXXXXXX XX XXXXXXXX XXXXXXXXX XXXXXX XXX XXX XXXXXX XXXXXXX XXXXXXXXXXX XXX XXX XXXXXXXX XXX XXX XXXXXXXXXXX XX XXXXXXXX XX XXXXXXXXX XXXXX XXXXXXX XXXXX XX XXXXXXXXX X, XXXX. XXXXXXXX-XXXXXX XXX XXXXXXXXXXXXX XXXXXXX XXX XXXXXX XXXXXXXXX XXX X XXXXX’X XXXXXXX XXXXXXXXXX XX XXX XXXXXXXXXXX, XXXX XX XXXXXX XXX XXXXXXXX XX XXXXXXXXXXX.

XXXX XX:
XXXXXXXX XX XXXXXXXXXX XXX XXX XXXXXXXXX XX XXXXXXXXXXXX XXXXXXXX XXXX XX XXXXXXXXXX XXXXXXXXX, XXXXX XXXXXXXXXX XXXXXXXXX, XXXXXXXXX XXXXXXXXX, XXXXX’X XXXXXXX, XXXXXXXXXX XXXXXXXXXXX, XXXXXX XXXXXXXXX XXX XXXXXXXXXX XXXXXXX. XXXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXX XXXXXXX XXXXXXXX XXXXXXXXXXXXXX XXXXXXX XXXX (XXXXX XXX XXXXXXXXXXX XXXXXXXXX). XXXXXXXX XX XXXXXXXX XXXX XXX XXXXXXXXXXXX XX XXXXXXXX, XXX., X XXXXXXX & XXXXXXX XXXXXXX. XXXXXX XXXX, XXXXXXXX-XXXXXX XXXXXXXXX XX XXXXXX XXXXX XXX XXXXXXXX XXXX XXXXXXXX XXX XXXXXXX XXXXXX XX XXXXXXX XXX XXXXXXXXXXXXX XXXXXXXXX, X XXXXX XXXXX XXXXXXXXXX XXXXXXXX XXXXXXXXX XX XXXXX XXX XXXXXX. XXXXXXXX-XXXXXX XXX XXXXXXXXX XXXXXXXXX XXXXXX XX XXXX XXXXXXXX XXXXXXX XX XXX X.X., XXXXX XXX XXXXXXX XXXXX XXXXXXX. XX XXXXXXXX XXXX, XXXXXXXX-XXXXXX XXX XXXXXXXX XXXXXXX XXXXX XXXXXXXXXXXX XXXXXXXXX XXXXXXXXX XXX XXXXXXXXXXX, XXXXXXXXXXXXXXXXX XXX XXXXXXXXXXXX XX XXXX XXXXXXXX XXX XXXXXXXXX, XXXXXXXXX XXXXXXXX-XXXXXX’X XXXXXX XX XXXXXXXXXXX XXXXXX XXXXXXXX XX XXXXX XXX XXXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXXXXX XXXXXXXXX XXXXXX XXX XXXXXXXXX. XXXXXXXXX XXXX XXXXXXXXXX XXXXXXXX XX XXXXXXXXX XX XXX XX, XXXXXXXX-XXXXXX’X XXXXXXXXX XXXXXX XXX XXXX XXXXXXXX XXXX XXX XXXXXX XXX XX XXXXX XXXXX XXX XXXXX XXXXXXXXXX XXXX XX XXXXXXXXX XXXXXX XXX XX. XXXXXXXX XXXX XXXXXXX X XXXXXXXXXXXXX XXXXXXXXX XXXXX XX XXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXXXXXXXX XX XXXX XXXXXXXX XX XXX XXXXXXXX-XXXXXX XXXXXXXXX XXXXXXXXX XXXXXXX XXXX XXX XXXX, XXX XXX XXXXX XX XXXXXXX XXXX XXXXXX XXXXX XXXXXXXXXX XXX XXX XXXXXXXXX XX XXX XXXX. XXX XXXXXXX XX XXX XXXXXXXX XX XXXXXXXX XXXXXXXXX XXXXXX XXX XXX XXXXXX XXXXXXX XXXXXXXXXXX XXX XXX XXXXXXXX XXX XXX XXXXXXXXXXX XX XXXXXXXX XX XXXXXXXXX XXXXX XXXXXXX XXXXX XX XXXXXXXXX X, XXXX. XXXXXXXX-XXXXXX XXX XXXXXXXXXXXXX XXXXXXX XXX XXXXXX XXXXXXXXX XXX X XXXXX’X XXXXXXX XXXXXXXXXX XX XXX XXXXXXXXXXX, XXXX XX XXXXXX XXX XXXXXXXX XX XXXXXXXXXXX. XX XXXXXXXX, XXXXXXXX-XXXXXX XXX XXXXXXXX XXXXXX XX XXXXXXX XX XXXXXXXXXXXX XXXXXX XX XXX XXXXXXXXXXXXXXXXX XX XXXXXXXXX XXX XXXXXXX XXXXXX XX XXXXX XXX XXXXXXXXXXX XXXXX. XXX XXX XXXXXX XX XXXX XXXXXX, XXXXXXXX-XXXXXX XXXX XX XXXXXXX XXXXXXX XX $XX XXXXXXX, XXXXX XX XXXXXXXX XX XXXXXXXX XXX XXXXXXXXXXX XXXXXXXX XXX XXX XXXX XXXXX XXXXXXXX XX, XXXX.

XXXX XX:
XXXXXXXXXXXXX XXX XXXXX XX XXXXXXXX, XXXX XX XX XXXXXXX XX $X.X XXXXXXX XX XXXX XX XXXXXXXX XX XXXX XXXXXX XX XXXXXXXXX XXXXXX XXXXXX, XXXXXXXX XXX XXXXXX XXXXXXXXXXX XXX X XXXXXXXXXX XXXXXX XXXX XXXXXXX XXXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXXXXXXXX XXX XXXXX XX XXXXXXXX, X XXXX XXX XXX XXXXXXXXX XX XXXXXX-XXXXXXXX XXXXXXXXXXXX XXXXXXXXX XXXX XX XXXXXXXXXX XXXXXXXXX, XXXXX XXXXXXXXXX XXXXXXXXX, XXXXXXXXX XXXXXXXXX, XXXXX’X XXXXXXX, XXXXXXXXXX XXXXXXXXXXX, XXXXXX XXXXXXXXX, XXX XXXXXXXXXX XXXXXXX, XXXX XX XX XXXXXXX XX $X.X XXXXXXX XX XXXX XX XXXXXXXX XX XXXX XXXXXX XX XXXXXXXXX XXXXXX XXXXXX, XXXXXXXX XXXXXXXXXXX XX XXXXXXX XXXXXXXXXXX XXX X XXXXXXXXX XXXXXX XXXX XXXXXXX XXXXXXXX. XXXXXXXXXXXXX XXX XXXXX XXXXXXXXX XX XXXXXXX XX XXXX XX $X.X XXXXXXX XX XXXXXXXX XX XXXX, XXX XX XXXXXXX XXXXXX, XXXXXXXX XXX XXXXXX XXXXXXXXXXX XXX X XXXXXXXXX XXXXXX XXXX XXXXXXX XXXXXXXX. XXXXXXXX XX XX XXXX-XXX XXXXXXXX, XXXXXXXX XX XXXXXXXX-XXXXXX XXXXXXX XX XXX X.X., XXXXX XXX XXXXXXX XXXXX XXXXXXX. XXXXXXXXXXX XXXXXXXX XXX XXX XXXXXXXXXXX XXXXXXXX XX XXXXX XXXX XXXX XXXXXXXXXX XXXXXX XXXX XXX XXXX.

XXXXXXXX XX $X:
X) +XXXX

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXX XXX XXXXX XX XXXXXXX XXXXX XXXXX, X XXXX-XXXXX XXXXXXXXXXXXXX XXXXX XXXXX XXX XXXXXXXXX, XXXX XX XXXXXXX XX $X.X XXXXXXX XX XXXX XX XXXXXXXX XX XXXX XXX XX XXXXXXXXX XXXXX XXXXXX XXX XXXXXXXXXX XXXXXXX, XXX XX XXXXXXX XX $XXX XXXXXXX XX XXXX XX XXXXXXXX XX XXXX, XX XXX XXXXXXX XXXXXXXX XXXXXXX X.X. XXX XXXXXXXXXXXXX XXXXXX XXXXX XX XXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXX XXX XXXXX XX XXXXXXX XXXXX XXXXX, X XXXX-XXXXX XXXXXXXXXXXXXX XXXXX XXXXX XXX XXXXXXXXX, XXXX X XXXXXXX XX $X.X XXXXXXX XX XXXX XX XXXXXXXX XX XXXX XXX XX XXXXXXXXX XXXXX XX XXX XXXXXXXXXXXXX XXXXXX XXX XX XXXXXXX XX $X.X XXXXXXX XX XXXX XX XXXXXXXX XX XXXX, XX XXX XXXXXXX XXXXXXXX XXXXXXX X.X. XXX XXXXXXXXXXXXX XXXXXX XXXXX XX XXXX. XXXXXXXXXXX XXXXXXXX XXXX XXXX XXXXXXXXXX XX XXXX XXX XXXX.

XXXXXXXX XX $X:
X) +XXX

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXX XXX XXXXX XX XXXXXXX XXXXXXXX, XXXXXXXXX XX XXXXXXX XX $XXX XXXXXXX XX XXXX XX XXXXXXXX XX XXXX XXX XX XXXXXXXXX XXXXX XXXXXX XXXXXXXXXX XXXXXXX, XXXXXXXXX XXXXX, XXXXX XXX XXXXXXX XXX XXXXXXXX XX XXXXXXXXX XXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXX XXX XXXXX XX XXXXXXX, X XXXXXXXXX XXX XXXXXXX XXXXX XX XXXXX XXXXXX, XXXXXXXXX XX XXXXXXX XX $X XXXXXXX XX XXXX XX XXXXXXXX XX XXXX XXX XX XXXXXXXXX XXXXX XXXXXX XXXXXXXXXX XXXXXXX. XXXXXX XXX XXXXX XXXXXXXXX XX XXXXXXX XX $XXX XXXXXXX XX XXXX XX XXXXXXXX XX XXXX XXX XX XXXXXXXXX XXXXX XXXXXX XXXXXXXXXX XXXXXXX, XXXXXXXXX XXXXX, XXXXX XXX XXXXXXX XXX XXXXXXXX XX XXXXXXXXX XXXX. XXXXXXX XXXX XXXX XXXXXX XXXXXXXXXXX XX XXX XX XX XXXX.

Company Specific NameCardiovasculars

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

Company Specific NameDermatologicals

Company Specific NameAllergy and Respiratory

XXXXXXXX:
X) XXXXX XX & XXX XXXXX.
X) XXXXX/XXXXXXXX-XXXXXX XXXXXXXXXXXXXXX XX XXXXX.